Adicet Bio, Inc. (ACET)
Healthcare • Biotechnology • $4.28 • MCap: 42,782,012
https://www.adicetbio.com • Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Ex-AAII
| Score | Price | 52 Week & Averages | Relative Strength | Risk | |||||
|---|---|---|---|---|---|---|---|---|---|
| Total | 32 | Current | $4.28 | 52W High | $14.43 -70.34% | Relative Strength | -0.51 | Beta | 1.63 |
| Business Quality | 1 | Weekly | $5.14 -16.73% | 52W Low | $4.28 0.00% | 3M | -0.45 | Short % | 0.05 |
| Financial Strength | 10 | Monthly | $9.15 -53.20% | Above 50DMA | $7.76 -44.86% | 6M | -0.46 | Risk Score | 9 |
| Growth Outlook | 1 | Quarterly | $7.79 -45.06% | Above 200DMA | $7.82 -45.29% | 9M | -0.49 | ||
| Momentum | 3 | Yearly | $14.43 -70.34% | 12M | -0.70 | ||||
| Valuation | Financial Strength | Growth/Profitability | |||
|---|---|---|---|---|---|
| Trailing P/E | N/A | Cash | 118M | Revenue Growth | N/A |
| Forward P/E | -1.13 | Debt | 13M | Earnings Growth | N/A |
| PEG Ratio | N/A | Debt/Equity | 10.70 | Qtr Earnings Growth | N/A |
| Price/Sales | N/A | Current Ratio | 6.71 | Gross Margin | 0.00% |
| Price/Book | 0.41 | Quick Ratio | 6.59 | Operating Margin | 0.00% |
| EV/Revenue | N/A | Operating CF | -85M | Profit Margin | 0.00% |
| EV/EBITDA | 0.57 | Free CF | -48M | EBITDA Margin | 0.00% |
| Ent Value | -56M | Return on Assets | -0.42% | ||
| Return on Equity | -0.78% | ||||
| Technical | Volume & Bollinger Bands | Analyst | |||
|---|---|---|---|---|---|
| RSI | 23.79 | Volume | 0.19M | Rating | strong_buy |
| Previous RSI | 25.14 | Avg Volume 20D | 0.35M | Target Mean | $34.83 |
| RSI Trend | Down | Relative Volume | 0.52 | Target High | $90.00 |
| MACD | -1.03 | Lower Band | 3.44 | Target Low | $18.00 |
| MACD Signal | -0.95 | Middle Band | 5.79 | Target Median | $24.00 |
| Histogram | -0.08 | Upper Band | 8.14 | Analysts | 6 |
| Previous Histogram | -0.10 | Bandwidth | 81.070 | Upside | 662.22% |
| Histogram Trend | Increasing | %B | 0.18 | ||
